164 related articles for article (PubMed ID: 27535746)
21. Monitoring the effects of BCNU chemotherapy Wafers (Gliadel) in glioblastoma multiforme with proton magnetic resonance spectroscopic imaging at 3.0 Tesla.
Dyke JP; Sanelli PC; Voss HU; Serventi JV; Stieg PE; Schwartz TH; Ballon D; Shungu DC; Pannullo SC
J Neurooncol; 2007 Mar; 82(1):103-10. PubMed ID: 17031552
[TBL] [Abstract][Full Text] [Related]
22. Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas.
Li X; Jin H; Lu Y; Oh J; Chang S; Nelson SJ
NMR Biomed; 2004 Feb; 17(1):10-20. PubMed ID: 15011246
[TBL] [Abstract][Full Text] [Related]
23. Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme.
Lupo JM; Essock-Burns E; Molinaro AM; Cha S; Chang SM; Butowski N; Nelson SJ
Neuro Oncol; 2013 Apr; 15(4):480-9. PubMed ID: 23393208
[TBL] [Abstract][Full Text] [Related]
24. Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study.
Zhu P; Du XL; Lu G; Zhu JJ
Oncotarget; 2017 Jul; 8(27):44015-44031. PubMed ID: 28467795
[TBL] [Abstract][Full Text] [Related]
25. Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo.
Ellingson BM; Abrey LE; Garcia J; Chinot O; Wick W; Saran F; Nishikawa R; Henriksson R; Mason WP; Harris RJ; Leu K; Woodworth DC; Mehta A; Raymond C; Chakhoyan A; Pope WB; Cloughesy TF
Neuro Oncol; 2018 Oct; 20(11):1525-1535. PubMed ID: 29897562
[TBL] [Abstract][Full Text] [Related]
26. Survival analysis in patients with newly diagnosed glioblastoma using pre- and postradiotherapy MR spectroscopic imaging.
Li Y; Lupo JM; Parvataneni R; Lamborn KR; Cha S; Chang SM; Nelson SJ
Neuro Oncol; 2013 May; 15(5):607-17. PubMed ID: 23393206
[TBL] [Abstract][Full Text] [Related]
27. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.
Narayana A; Gruber D; Kunnakkat S; Golfinos JG; Parker E; Raza S; Zagzag D; Eagan P; Gruber ML
J Neurosurg; 2012 Feb; 116(2):341-5. PubMed ID: 22035272
[TBL] [Abstract][Full Text] [Related]
28. [Application of (1)H MR spectroscopic imaging in radiation oncology: choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors].
Lichy MP; Bachert P; Hamprecht F; Weber MA; Debus J; Schulz-Ertner D; Schlemmer HP; Kauczor HU
Rofo; 2006 Jun; 178(6):627-33. PubMed ID: 16703499
[TBL] [Abstract][Full Text] [Related]
29. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
Vredenburgh JJ; Desjardins A; Kirkpatrick JP; Reardon DA; Peters KB; Herndon JE; Marcello J; Bailey L; Threatt S; Sampson J; Friedman A; Friedman HS
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):58-66. PubMed ID: 21036490
[TBL] [Abstract][Full Text] [Related]
30. [Pseudoprogression or pseudoresponse: a challenge for the diagnostic imaging in Glioblastoma multiforme].
Payer F
Wien Med Wochenschr; 2011 Jan; 161(1-2):13-9. PubMed ID: 21312094
[TBL] [Abstract][Full Text] [Related]
31. Magnetic resonance spectroscopic imaging for visualization of the infiltration zone of glioma.
Stadlbauer A; Buchfelder M; Doelken MT; Hammen T; Ganslandt O
Cent Eur Neurosurg; 2011 May; 72(2):63-9. PubMed ID: 20635312
[TBL] [Abstract][Full Text] [Related]
32. Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma.
Tsien CI; Brown D; Normolle D; Schipper M; Piert M; Junck L; Heth J; Gomez-Hassan D; Ten Haken RK; Chenevert T; Cao Y; Lawrence T
Clin Cancer Res; 2012 Jan; 18(1):273-9. PubMed ID: 22065084
[TBL] [Abstract][Full Text] [Related]
33. MR spectroscopy using normalized and non-normalized metabolite ratios for differentiating recurrent brain tumor from radiation injury.
Elias AE; Carlos RC; Smith EA; Frechtling D; George B; Maly P; Sundgren PC
Acad Radiol; 2011 Sep; 18(9):1101-8. PubMed ID: 21820634
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.
Boxerman JL; Zhang Z; Safriel Y; Rogg JM; Wolf RL; Mohan S; Marques H; Sorensen AG; Gilbert MR; Barboriak DP
Neuro Oncol; 2018 Sep; 20(10):1400-1410. PubMed ID: 29590461
[TBL] [Abstract][Full Text] [Related]
35. Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy.
Guillevin R; Menuel C; Taillibert S; Capelle L; Costalat R; Abud L; Habas C; De Marco G; Hoang-Xuan K; Chiras J; Vallée JN
Br J Cancer; 2011 Jun; 104(12):1854-61. PubMed ID: 21610707
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR
Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484
[TBL] [Abstract][Full Text] [Related]
37. Major Metabolite Levels of Preoperative Proton Magnetic Resonance Sectroscopy and Intraoperative Fluorescence Intensity in Glioblastoma.
Tian HL; Zu YL; Wang CC; Lin T; Guo ZT; Jiang B; Yin X; Guo WQ; Wang ZG
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):511-517. PubMed ID: 28877829
[TBL] [Abstract][Full Text] [Related]
38. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
[TBL] [Abstract][Full Text] [Related]
39. The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping.
Bulik M; Kazda T; Slampa P; Jancalek R
Biomed Res Int; 2015; 2015():641023. PubMed ID: 26448943
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma.
Ney DE; Carlson JA; Damek DM; Gaspar LE; Kavanagh BD; Kleinschmidt-DeMasters BK; Waziri AE; Lillehei KO; Reddy K; Chen C
J Neurooncol; 2015 Mar; 122(1):135-43. PubMed ID: 25524817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
